Stockscreener 앱 받기
15.20
4.47%
0.65
시간 외 거래:
15.43
0.23
+1.51%
전일 마감가:
$14.55
열려 있는:
$14.87
하루 거래량:
12.42M
Relative Volume:
2.12
시가총액:
$2.12B
수익:
$67.67M
순이익/손실:
$-412.69M
주가수익비율:
-3.9722
EPS:
-3.8266
순현금흐름:
$-395.87M
1주 성능:
+24.59%
1개월 성능:
+11.19%
6개월 성능:
+72.92%
1년 성능:
+58.66%
1일 변동 폭
$14.43
$16.73
1주일 범위
$11.81
$16.73
52주 변동 폭
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
15.20 | 2.08B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-10-28 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Canaccord reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Canada
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $19 - Moomoo
Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR) - The Globe and Mail
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results - Insider Monkey
Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus - TechStock²
Intellia Therapeutics jumps after additional Phase 3 HAE data and peer-reviewed publication reinforce lonvo-z outlook - Quiver Quantitative
Why is Intellia Therapeutics stock surging today? By Investing.com - Investing.com Canada
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia Therapeutics | 8-K: Current report - Moomoo
NTLA Reiterated by Wedbush -- Price Target Maintained at $12.00 - GuruFocus
NTLA Reiterated by Citizens -- Price Target Maintained at $30 - GuruFocus
Intellia Therapeutics options trading jumps to 7,041 contracts - Investing.com
Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com - Investing.com India
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9 - Moomoo
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder - Benzinga
Intellia Reports Strong Phase 3 Results for lonvo-z, 87% fewer monthly attacks; BLA rolling, U.S. launch H1 2027 - TradingView
Phase 3 HAELO data support Intellia (NTLA) lonvo-z as potential one-time therapy - Stock Titan
Why is NTLA stock jumping 5% premarket today? - MSN
H.C. Wainwright reiterates Intellia stock rating on positive trial data - Investing.com
H.C. Wainwright reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Canada
Positive Phase III results for Intellia’s lonvo-z - The Pharma Letter
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on positive trial data - Investing.com
William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating - Moomoo
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN
Intellia Therapeutics (NTLA) Reports Promising Phase 3 Trial Res - GuruFocus
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Intellia presents Phase 3 results for HAE gene therapy lonvo-z - Investing.com UK
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics
Intellia presents Phase 3 results for HAE gene therapy lonvo-z By Investing.com - Investing.com India
Intellia Therapeutics Says Haleo Met Its Primary Endpoint With An 87% Reduction (P - TradingView
One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial - Stock Titan
Intellia Shareholders Back Board, Executive Pay and Auditor - The Globe and Mail
Exploring High Growth Tech Stocks In The US Market - simplywall.st
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bhanji Muna - Moomoo
Intellia (NTLA) director receives 9,200 RSUs and 13,300 options - Stock Titan
Intellia (NTLA) director Georgia Keresty receives stock awards and options grant - Stock Titan
Intellia Therapeutics (NTLA) director receives stock and option awards - Stock Titan
Intellia (NTLA) director Brian Goff receives RSU and stock option grants - Stock Titan
Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options - Stock Titan
Intellia (NTLA) director awarded RSUs and stock options in new grant - Stock Titan
Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options - Stock Titan
Intellia Therapeutics (NTLA) posts 2026 shareholder voting results - Stock Titan
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Singapore
Draft FDA guidance could be a boon for gene therapy developers - MSN
Intellia Therapeutics Stock Short Interest Rises to 46.78% - Quiver Quantitative
Intellia Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Intellia Therapeutics, Inc. Trade Ideas — XETR:38I - TradingView
Average basic shares outstanding of Intellia Therapeutics, Inc. – XETR:38I - TradingView
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Intellia Therapeutics Inc 주식 (NTLA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 02 '26 |
Sale |
13.78 |
607 |
8,364 |
93,864 |
| LEONARD JOHN M | President and CEO |
Jan 05 '26 |
Sale |
9.21 |
34,146 |
314,485 |
1,013,339 |
| Schultes Birgit C | EVP, Chief Scientific Officer |
Jan 05 '26 |
Sale |
9.21 |
8,508 |
78,359 |
98,533 |
| BASTA JAMES | EVP, General Counsel |
Jan 05 '26 |
Sale |
9.21 |
10,397 |
95,756 |
101,528 |
| Cohen Fred E | Director |
Jan 05 '26 |
Buy |
9.35 |
150,000 |
1,402,500 |
207,453 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 05 '26 |
Sale |
9.21 |
11,903 |
109,627 |
121,249 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 05 '26 |
Sale |
9.21 |
9,515 |
87,633 |
87,118 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jan 05 '26 |
Sale |
9.21 |
6,379 |
58,751 |
99,683 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 05 '26 |
Sale |
9.21 |
2,989 |
27,529 |
52,277 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Option Exercise |
6.83 |
49,959 |
341,220 |
1,127,074 |
2.60%
0.94%
자본화:
|
볼륨(24시간):